Andrew Leger
Genzyme
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrew Leger.
Nature | 2012
Thurman M. Wheeler; Andrew Leger; Sanjay K. Pandey; A. Robert MacLeod; Masayuki Nakamori; Seng H. Cheng; Bruce M. Wentworth; C. Frank Bennett; Charles A. Thornton
Antisense oligonucleotides (ASOs) hold promise for gene-specific knockdown in diseases that involve RNA or protein gain-of-function effects. In the hereditary degenerative disease myotonic dystrophy type 1 (DM1), transcripts from the mutant allele contain an expanded CUG repeat and are retained in the nucleus. The mutant RNA exerts a toxic gain-of-function effect, making it an appropriate target for therapeutic ASOs. However, despite improvements in ASO chemistry and design, systemic use of ASOs is limited because uptake in many tissues, including skeletal and cardiac muscle, is not sufficient to silence target messenger RNAs. Here we show that nuclear-retained transcripts containing expanded CUG (CUGexp) repeats are unusually sensitive to antisense silencing. In a transgenic mouse model of DM1, systemic administration of ASOs caused a rapid knockdown of CUGexp RNA in skeletal muscle, correcting the physiological, histopathologic and transcriptomic features of the disease. The effect was sustained for up to 1 year after treatment was discontinued. Systemically administered ASOs were also effective for muscle knockdown of Malat1, a long non-coding RNA (lncRNA) that is retained in the nucleus. These results provide a general strategy to correct RNA gain-of-function effects and to modulate the expression of expanded repeats, lncRNAs and other transcripts with prolonged nuclear residence.
Molecular therapy. Nucleic acids | 2014
Nicholas P. Clayton; Carol A. Nelson; Timothy E. Weeden; Kristin M. Taylor; Rodney J. Moreland; Ronald K. Scheule; Lucy Phillips; Andrew Leger; Seng H. Cheng; Bruce M. Wentworth
Pompe disease is an autosomal recessive disorder caused by a deficiency of acid α-glucosidase (GAA; EC 3.2.1.20) and the resultant progressive lysosomal accumulation of glycogen in skeletal and cardiac muscles. Enzyme replacement therapy using recombinant human GAA (rhGAA) has proven beneficial in addressing several aspects of the disease such as cardiomyopathy and aberrant motor function. However, residual muscle weakness, hearing loss, and the risks of arrhythmias and osteopenia persist despite enzyme therapy. Here, we evaluated the relative merits of substrate reduction therapy (by inhibiting glycogen synthesis) as a potential adjuvant strategy. A phosphorodiamidate morpholino oligonucleotide (PMO) designed to invoke exon skipping and premature stop codon usage in the transcript for muscle specific glycogen synthase (Gys1) was identified and conjugated to a cell penetrating peptide (GS-PPMO) to facilitate PMO delivery to muscle. GS-PPMO systemic administration to Pompe mice led to a dose-dependent decrease in glycogen synthase transcripts in the quadriceps, and the diaphragm but not the liver. An mRNA response in the heart was seen only at the higher dose tested. Associated with these decreases in transcript levels were correspondingly lower tissue levels of muscle specific glycogen synthase and activity. Importantly, these reductions resulted in significant decreases in the aberrant accumulation of lysosomal glycogen in the quadriceps, diaphragm, and heart of Pompe mice. Treatment was without any overt toxicity, supporting the notion that substrate reduction by GS-PPMO-mediated inhibition of muscle specific glycogen synthase represents a viable therapeutic strategy for Pompe disease after further development.
Journal of Bone and Mineral Metabolism | 2010
Andrew Leger; Allison Altobelli; Leocadia M. Mosquea; Adam J. Belanger; Antonius Song; Seng H. Cheng; Canwen Jiang; Nelson S. Yew
Studies examining the effects of hypoxia upon osteoclast biology have consistently revealed a stimulatory effect; both osteoclast differentiation and resorption activity have been shown to be enhanced in the presence of hypoxia. In the present study we examined the effects of the hypoxia mimetics dimethyloxallyl glycine (DMOG) and desferrioxamine (DFO) upon osteoclastogenesis. In contrast to hypoxia, our studies revealed a dose-dependent inhibition of osteoclast formation from macrophages treated with DMOG and DFO. Moreover, expression of a constitutively active form of hypoxia-inducible factor 1α (HIF-1α) did not enhance osteoclastogenesis and actually attenuated the differentiation process. DMOG did not affect cell viability or receptor activator of nuclear factor κB ligand (RANKL)-dependent phosphorylation of mitogen-activated protein (MAP) kinases. However, RANKL-dependent transcription of tartrate-resistant acid phosphatase (TRAP) was reduced in the presence of DMOG. Additionally, DMOG promoted transcription of the pro-apoptotic mediator B-Nip3. These studies suggest that a hypoxia-responsive factor other than HIF-1α is necessary for enhancing the formation of osteoclasts in hypoxic settings.
Journal of Gene Medicine | 2011
Andrew Leger; Leocadia M. Mosquea; Lingyun Li; Wei-Lien Chuang; Joshua Pacheco; Kristin M. Taylor; Zhengyu Luo; Peter A. Piepenhagen; Robin J. Ziegler; Rod Moreland; Akihiro Urabe; Canwen Jiang; Seng H. Cheng; Nelson S. Yew
The secretory form of acid sphingomyelinase (ASM) is postulated to play a key role in the retention and aggregation of lipoproteins in the subendothelial space of the arterial wall by converting sphingomyelin in lipoproteins into ceramide. The present study aimed to determine whether the level of circulating ASM activity affects lesion development in mouse model of atherosclerosis.
Nucleic Acid Therapeutics | 2013
Andrew Leger; Leocadia M. Mosquea; Nicholas P. Clayton; I-Huan Wu; Timothy E. Weeden; Carol A. Nelson; Lucy Phillips; Errin Roberts; Peter A. Piepenhagen; Seng H. Cheng; Bruce M. Wentworth
Archive | 2013
Andrew Leger; Bruce M. Wentworth; Carol A. Nelson; Timothy E. Weeden; Nicholas P. Clayton; Seng Cheng
Archive | 2011
Jozsef Karman; Canwen Jiang; James Dodge; Nelson S. Yew; Yunxiang Zhu; Seng H. Cheng; Hongmei Zhao; Andrew Leger; Kenneth W. Dobie; Ravi Jain
Archive | 2017
Timothy E. Weeden; Carol A. Nelson; Bruce M. Wentworth; Nicholas P. Clayton; Andrew Leger
Molecular Genetics and Metabolism | 2015
Nicholas P. Clayton; Carol A. Nelson; Timothy E. Weeden; Kristin M. Taylor; Rodney J. Moreland; Ronald K. Scheule; Andrew Leger; Lucy Phillips; Seng H. Cheng; Bruce M. Wentworth
Molecular Genetics and Metabolism | 2013
Andrew Leger